Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

Hartmut H J Schmidt, Fabio Barroso, Alejandra González-Duarte, Isabel Conceição, Laura Obici, Denis Keohane, Leslie Amass

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare, severe, and irreversible, adult-onset, hereditary disorder caused by autosomal-dominant mutations in the TTR gene that increase the intrinsic propensity of transthyretin protein to misfold and deposit systemically as insoluble amyloid fibrils in nerve tissues, the heart, and other organs. TTR-FAP is characterized by relentless, progressively debilitating polyneuropathy, and leads to death, on average, within 10 years of symptom onset without treatment. With increased availability of disease-modifying treatment options for a wider spectrum of patients with TTR-FAP, timely detection of the disease may offer substantial clinical benefits. This review discusses mutation-specific predictive genetic testing in first-degree relatives of index patients diagnosed with TTR-FAP and the structured clinical follow-up of asymptomatic gene carriers for prompt diagnosis and early therapeutic intervention before accumulation of substantial damage. Muscle Nerve 54: 353–360, 2016.

Original languageEnglish
Pages (from-to)353-360
Number of pages8
JournalMuscle and Nerve
Volume54
Issue number3
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Familial Amyloid Neuropathies
Prealbumin
Genes
Lead Poisoning, Nervous System, Adult
Nerve Tissue
Mutation
Genetic Testing
Amyloid
Therapeutics
Muscles
Proteins

Keywords

  • amyloidosis
  • carrier
  • familial amyloid polyneuropathy
  • predictive genetic testing
  • transthyretin

ASJC Scopus subject areas

  • Physiology
  • Medicine(all)
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Schmidt, H. H. J., Barroso, F., González-Duarte, A., Conceição, I., Obici, L., Keohane, D., & Amass, L. (2016). Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle and Nerve, 54(3), 353-360. https://doi.org/10.1002/mus.25210

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. / Schmidt, Hartmut H J; Barroso, Fabio; González-Duarte, Alejandra; Conceição, Isabel; Obici, Laura; Keohane, Denis; Amass, Leslie.

In: Muscle and Nerve, Vol. 54, No. 3, 01.09.2016, p. 353-360.

Research output: Contribution to journalArticle

Schmidt, HHJ, Barroso, F, González-Duarte, A, Conceição, I, Obici, L, Keohane, D & Amass, L 2016, 'Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy', Muscle and Nerve, vol. 54, no. 3, pp. 353-360. https://doi.org/10.1002/mus.25210
Schmidt HHJ, Barroso F, González-Duarte A, Conceição I, Obici L, Keohane D et al. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle and Nerve. 2016 Sep 1;54(3):353-360. https://doi.org/10.1002/mus.25210
Schmidt, Hartmut H J ; Barroso, Fabio ; González-Duarte, Alejandra ; Conceição, Isabel ; Obici, Laura ; Keohane, Denis ; Amass, Leslie. / Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. In: Muscle and Nerve. 2016 ; Vol. 54, No. 3. pp. 353-360.
@article{b53e0aec80534c479039dff2cc4afe67,
title = "Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy",
abstract = "Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare, severe, and irreversible, adult-onset, hereditary disorder caused by autosomal-dominant mutations in the TTR gene that increase the intrinsic propensity of transthyretin protein to misfold and deposit systemically as insoluble amyloid fibrils in nerve tissues, the heart, and other organs. TTR-FAP is characterized by relentless, progressively debilitating polyneuropathy, and leads to death, on average, within 10 years of symptom onset without treatment. With increased availability of disease-modifying treatment options for a wider spectrum of patients with TTR-FAP, timely detection of the disease may offer substantial clinical benefits. This review discusses mutation-specific predictive genetic testing in first-degree relatives of index patients diagnosed with TTR-FAP and the structured clinical follow-up of asymptomatic gene carriers for prompt diagnosis and early therapeutic intervention before accumulation of substantial damage. Muscle Nerve 54: 353–360, 2016.",
keywords = "amyloidosis, carrier, familial amyloid polyneuropathy, predictive genetic testing, transthyretin",
author = "Schmidt, {Hartmut H J} and Fabio Barroso and Alejandra Gonz{\'a}lez-Duarte and Isabel Concei{\cc}{\~a}o and Laura Obici and Denis Keohane and Leslie Amass",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/mus.25210",
language = "English",
volume = "54",
pages = "353--360",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy

AU - Schmidt, Hartmut H J

AU - Barroso, Fabio

AU - González-Duarte, Alejandra

AU - Conceição, Isabel

AU - Obici, Laura

AU - Keohane, Denis

AU - Amass, Leslie

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare, severe, and irreversible, adult-onset, hereditary disorder caused by autosomal-dominant mutations in the TTR gene that increase the intrinsic propensity of transthyretin protein to misfold and deposit systemically as insoluble amyloid fibrils in nerve tissues, the heart, and other organs. TTR-FAP is characterized by relentless, progressively debilitating polyneuropathy, and leads to death, on average, within 10 years of symptom onset without treatment. With increased availability of disease-modifying treatment options for a wider spectrum of patients with TTR-FAP, timely detection of the disease may offer substantial clinical benefits. This review discusses mutation-specific predictive genetic testing in first-degree relatives of index patients diagnosed with TTR-FAP and the structured clinical follow-up of asymptomatic gene carriers for prompt diagnosis and early therapeutic intervention before accumulation of substantial damage. Muscle Nerve 54: 353–360, 2016.

AB - Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare, severe, and irreversible, adult-onset, hereditary disorder caused by autosomal-dominant mutations in the TTR gene that increase the intrinsic propensity of transthyretin protein to misfold and deposit systemically as insoluble amyloid fibrils in nerve tissues, the heart, and other organs. TTR-FAP is characterized by relentless, progressively debilitating polyneuropathy, and leads to death, on average, within 10 years of symptom onset without treatment. With increased availability of disease-modifying treatment options for a wider spectrum of patients with TTR-FAP, timely detection of the disease may offer substantial clinical benefits. This review discusses mutation-specific predictive genetic testing in first-degree relatives of index patients diagnosed with TTR-FAP and the structured clinical follow-up of asymptomatic gene carriers for prompt diagnosis and early therapeutic intervention before accumulation of substantial damage. Muscle Nerve 54: 353–360, 2016.

KW - amyloidosis

KW - carrier

KW - familial amyloid polyneuropathy

KW - predictive genetic testing

KW - transthyretin

UR - http://www.scopus.com/inward/record.url?scp=84982141329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982141329&partnerID=8YFLogxK

U2 - 10.1002/mus.25210

DO - 10.1002/mus.25210

M3 - Article

C2 - 27273296

AN - SCOPUS:84982141329

VL - 54

SP - 353

EP - 360

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 3

ER -